Jafron Biomedical

Jafron Biomedical, established in 1989, is a pioneer enterprise in the hemoadsorption industry. This A-shared GEM listed corporation specializes in providing comprehensive blood purification solutions. Its product portfolio includes HA Series Hemoperfusion Cartridges, BS Bilirubin Adsorption Column, and DNA Immunoadsorption Column, leveraging advanced adsorption technologies. The company's commitment to innovation has positioned it as a leader in developing cutting-edge medical devices for critical care and chronic disease management.

With a significant global footprint, Jafron Biomedical's therapies are utilized annually in over 3 million cases across more than 80 countries and 6,000 major hospitals worldwide. The company operates with an employee range of 1,000-5,000 individuals dedicated to advancing blood purification technologies. Supported by its Global Advisory Board, Jafron Biomedical actively contributes to the global medical community through extensive research and guidance in blood purification and its associated cutting-edge technologies. Meet Jafron Biomedical's team to understand the expertise driving these global initiatives.

Operating within the Pharmaceuticals and Healthcare sectors, Jafron Biomedical focuses on B2B markets, particularly in Asia Pacific. Its revenue reached $974.6M, underscoring its substantial market presence. The company's strategic direction involves continuous research and development to expand the applications of hemoadsorption therapy, aiming to improve patient outcomes and address unmet medical needs globally. Jafron Biomedical's long-standing history and focus on specialized medical devices highlight its enduring impact on the healthcare landscape.